Stage IV Ovarian Cancer: Evelyn's Survivor Story

This ovarian cancer diagnosis at a glance

Stage at diagnosis
Stage IV
Biomarkers
HRD-positive
Sex
female
Treatment
chemotherapy, surgery and targeted therapy
Outcome
Cancer-Free / NED

Treatment course, step by step

  1. Started chemotherapy on November 2, 2022.
  2. Underwent surgery after 4 chemotherapy treatments.
  3. Completed chemotherapy in May 2023 with an unremarkable final scan.
  4. Started Lynparza in June 2023 as PARP-inhibitor maintenance therapy and continued it for 2 years.

What happened, in summary

Evelyn was diagnosed with Stage IV ovarian cancer on October 17, 2022, after months of abdominal swelling, fatigue, and other changes she had initially attributed to menopause. She began chemotherapy on November 2 and approached treatment by asking detailed questions and building a support system around herself.

After 4 chemotherapy treatments, Evelyn underwent surgery and then completed the remaining chemotherapy. She described the surgery as successful and said her final scan in May 2023 was unremarkable. Tumor testing later showed that her cancer was HRD-positive, a result that made her eligible for a PARP inhibitor.

Evelyn started Lynparza in June 2023 as maintenance therapy and continued it for 2 years. She experienced joint pain and fatigue but remained committed to treatment. Looking back, she emphasized how biomarker testing changed her options and helped her understand why an additional therapy was being recommended. Her story highlights the value of asking about tumor testing early and using the results to guide treatment decisions.

Where this story comes from

This is a lay summary of an account first published by National Ovarian Cancer Coalition. Read the original in full

How we source and attribute stories Accuracy and limitations

Collections this story belongs to

Similar ovarian cancer stories

These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer

Search more ovarian cancer stories